Unrelated cord blood transplantation in CML: Japan Cord Blood Bank Network analysis

T. Nagamura-Inoue, S. Kai, H. Azuma, M. Takanashi, K. Isoyama, K. Kato, S. Takahashi, S. Taniguchi, K. Miyamura, K. Aoki, M. Hidaka, F. Nagamura, A. Tojo, X. M. Fang, S. Kato

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

We analysed 86 patients with CML who received unrelated cord blood transplantation (UCBT), identified through a registry of the Japan Cord Blood Bank Network. At transplantation, the median patient age was 39 years (range, 1-67 years); 38 patients were in chronic phase (CP), 13 in the accelerated phase (AP) and 35 in blast crisis (BC). Median duration from diagnosis to UCBT was 1.5 years (range, 0.2-14.6 years). A nucleated cell (NC) dose of more than 3.0 × 107 per kg was sufficient to achieve neutrophil (91%) and platelet recovery (86%), whereas the lower dose of NC achieved only 60 and 61%, respectively. The duration and type of pre-transplant treatment did not affect neutrophil or platelet recovery. Results of multivariate analysis indicated that older patients (>50 years) had a higher incidence of transplant-related mortality. Advanced-disease stage and lower doses of NCs were significantly associated with lower leukaemia-free and event-free survival. At 2-year survival for patients in CP, AP and BC was 71, 59 and 32%, respectively (P=0.0004). A pre-transplant European Group for Blood and Marrow Transplantation scoring system was effective in predicting the outcome of UCBT. We conclude that UCBT is a reasonable alternative therapy for patients with CML.

Original languageEnglish
Pages (from-to)241-251
Number of pages11
JournalBone Marrow Transplantation
Volume42
Issue number4
DOIs
Publication statusPublished - Jul 22 2008
Externally publishedYes

Fingerprint

Blood Banks
Fetal Blood
Japan
Transplantation
Blast Crisis
Transplants
Neutrophils
Blood Platelets
Complementary Therapies
Disease-Free Survival
Registries
Leukemia
Multivariate Analysis
Survival
Mortality
Incidence

All Science Journal Classification (ASJC) codes

  • Hematology
  • Transplantation

Cite this

Nagamura-Inoue, T., Kai, S., Azuma, H., Takanashi, M., Isoyama, K., Kato, K., ... Kato, S. (2008). Unrelated cord blood transplantation in CML: Japan Cord Blood Bank Network analysis. Bone Marrow Transplantation, 42(4), 241-251. https://doi.org/10.1038/bmt.2008.164

Unrelated cord blood transplantation in CML : Japan Cord Blood Bank Network analysis. / Nagamura-Inoue, T.; Kai, S.; Azuma, H.; Takanashi, M.; Isoyama, K.; Kato, K.; Takahashi, S.; Taniguchi, S.; Miyamura, K.; Aoki, K.; Hidaka, M.; Nagamura, F.; Tojo, A.; Fang, X. M.; Kato, S.

In: Bone Marrow Transplantation, Vol. 42, No. 4, 22.07.2008, p. 241-251.

Research output: Contribution to journalArticle

Nagamura-Inoue, T, Kai, S, Azuma, H, Takanashi, M, Isoyama, K, Kato, K, Takahashi, S, Taniguchi, S, Miyamura, K, Aoki, K, Hidaka, M, Nagamura, F, Tojo, A, Fang, XM & Kato, S 2008, 'Unrelated cord blood transplantation in CML: Japan Cord Blood Bank Network analysis', Bone Marrow Transplantation, vol. 42, no. 4, pp. 241-251. https://doi.org/10.1038/bmt.2008.164
Nagamura-Inoue, T. ; Kai, S. ; Azuma, H. ; Takanashi, M. ; Isoyama, K. ; Kato, K. ; Takahashi, S. ; Taniguchi, S. ; Miyamura, K. ; Aoki, K. ; Hidaka, M. ; Nagamura, F. ; Tojo, A. ; Fang, X. M. ; Kato, S. / Unrelated cord blood transplantation in CML : Japan Cord Blood Bank Network analysis. In: Bone Marrow Transplantation. 2008 ; Vol. 42, No. 4. pp. 241-251.
@article{6bcd6488d99c4d63839492d07ff4dde9,
title = "Unrelated cord blood transplantation in CML: Japan Cord Blood Bank Network analysis",
abstract = "We analysed 86 patients with CML who received unrelated cord blood transplantation (UCBT), identified through a registry of the Japan Cord Blood Bank Network. At transplantation, the median patient age was 39 years (range, 1-67 years); 38 patients were in chronic phase (CP), 13 in the accelerated phase (AP) and 35 in blast crisis (BC). Median duration from diagnosis to UCBT was 1.5 years (range, 0.2-14.6 years). A nucleated cell (NC) dose of more than 3.0 × 107 per kg was sufficient to achieve neutrophil (91{\%}) and platelet recovery (86{\%}), whereas the lower dose of NC achieved only 60 and 61{\%}, respectively. The duration and type of pre-transplant treatment did not affect neutrophil or platelet recovery. Results of multivariate analysis indicated that older patients (>50 years) had a higher incidence of transplant-related mortality. Advanced-disease stage and lower doses of NCs were significantly associated with lower leukaemia-free and event-free survival. At 2-year survival for patients in CP, AP and BC was 71, 59 and 32{\%}, respectively (P=0.0004). A pre-transplant European Group for Blood and Marrow Transplantation scoring system was effective in predicting the outcome of UCBT. We conclude that UCBT is a reasonable alternative therapy for patients with CML.",
author = "T. Nagamura-Inoue and S. Kai and H. Azuma and M. Takanashi and K. Isoyama and K. Kato and S. Takahashi and S. Taniguchi and K. Miyamura and K. Aoki and M. Hidaka and F. Nagamura and A. Tojo and Fang, {X. M.} and S. Kato",
year = "2008",
month = "7",
day = "22",
doi = "10.1038/bmt.2008.164",
language = "English",
volume = "42",
pages = "241--251",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Unrelated cord blood transplantation in CML

T2 - Japan Cord Blood Bank Network analysis

AU - Nagamura-Inoue, T.

AU - Kai, S.

AU - Azuma, H.

AU - Takanashi, M.

AU - Isoyama, K.

AU - Kato, K.

AU - Takahashi, S.

AU - Taniguchi, S.

AU - Miyamura, K.

AU - Aoki, K.

AU - Hidaka, M.

AU - Nagamura, F.

AU - Tojo, A.

AU - Fang, X. M.

AU - Kato, S.

PY - 2008/7/22

Y1 - 2008/7/22

N2 - We analysed 86 patients with CML who received unrelated cord blood transplantation (UCBT), identified through a registry of the Japan Cord Blood Bank Network. At transplantation, the median patient age was 39 years (range, 1-67 years); 38 patients were in chronic phase (CP), 13 in the accelerated phase (AP) and 35 in blast crisis (BC). Median duration from diagnosis to UCBT was 1.5 years (range, 0.2-14.6 years). A nucleated cell (NC) dose of more than 3.0 × 107 per kg was sufficient to achieve neutrophil (91%) and platelet recovery (86%), whereas the lower dose of NC achieved only 60 and 61%, respectively. The duration and type of pre-transplant treatment did not affect neutrophil or platelet recovery. Results of multivariate analysis indicated that older patients (>50 years) had a higher incidence of transplant-related mortality. Advanced-disease stage and lower doses of NCs were significantly associated with lower leukaemia-free and event-free survival. At 2-year survival for patients in CP, AP and BC was 71, 59 and 32%, respectively (P=0.0004). A pre-transplant European Group for Blood and Marrow Transplantation scoring system was effective in predicting the outcome of UCBT. We conclude that UCBT is a reasonable alternative therapy for patients with CML.

AB - We analysed 86 patients with CML who received unrelated cord blood transplantation (UCBT), identified through a registry of the Japan Cord Blood Bank Network. At transplantation, the median patient age was 39 years (range, 1-67 years); 38 patients were in chronic phase (CP), 13 in the accelerated phase (AP) and 35 in blast crisis (BC). Median duration from diagnosis to UCBT was 1.5 years (range, 0.2-14.6 years). A nucleated cell (NC) dose of more than 3.0 × 107 per kg was sufficient to achieve neutrophil (91%) and platelet recovery (86%), whereas the lower dose of NC achieved only 60 and 61%, respectively. The duration and type of pre-transplant treatment did not affect neutrophil or platelet recovery. Results of multivariate analysis indicated that older patients (>50 years) had a higher incidence of transplant-related mortality. Advanced-disease stage and lower doses of NCs were significantly associated with lower leukaemia-free and event-free survival. At 2-year survival for patients in CP, AP and BC was 71, 59 and 32%, respectively (P=0.0004). A pre-transplant European Group for Blood and Marrow Transplantation scoring system was effective in predicting the outcome of UCBT. We conclude that UCBT is a reasonable alternative therapy for patients with CML.

UR - http://www.scopus.com/inward/record.url?scp=51049114261&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=51049114261&partnerID=8YFLogxK

U2 - 10.1038/bmt.2008.164

DO - 10.1038/bmt.2008.164

M3 - Article

C2 - 18574449

AN - SCOPUS:51049114261

VL - 42

SP - 241

EP - 251

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 4

ER -